"The key process patents for the first-generation of rhEPOs have expired in the EU and other regions, opening the market for biosimilar follow-on products. In addition, confronted with imminent patent expiration, the manufacturers of the innovative compounds have developed second-generation products with improved pharmacokinetic properties."
sounds like BALCO style things can happen with ESA's and biosimilar products of rhEPO....like how "the clear" aka THG was invented. there is a LARGE market for undetectable biosimilar rhEPO products, your the chemist and you take a fatty cut from say the berlin marathon...you prob doing better than working at walgreens.
but im sure all this medical mumbo jumbo is far below the intelligence of the EPO gurus that rule LR.
so from my limited knowledge of medical stuff, what i got from this paper was creating EPO is pretty advanced especially for 1977. using mammalian cells (sounds like STEM cell growth), to "grow" hybrid EPO. and how you manufacture this hybrid EPO in the cell is how it gets its name
‘epoetin’ : Eucaryotic cell-derived rhEPO, whose peptide core is identical with that of human urinary EPO
‘darbepoetin’ : Changes in the amino acid sequence are indicated by a different prefix
Analogues of a given EPO type substance with an altered glycosylation pattern due to production in a different host cell system are classified by a Greek letter added to the name (‘epoetin-ω’ vs. ‘epoetin-α’)
but you know, its just regular ol EPO and it is a placebo that dont do nothing right? yeah the lid is coming off and it took kenya's abuse of it to make it happen